SDZ 220-581

SDZ 220-581 是一种具有口服活性、强效、竞争性 NMDA 受体拮抗剂，pKi 值为 7.7。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
10mg

￥1300.00

1040.00

- +
50mg

￥5000.00

4000.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci20478
CAS: 174575-17-8
别名: (S)-ALPHA-氨基-2'-氯-5-(膦酰基甲基)-[1,1'-联苯]-3-丙酸,SDZ 220 581
分子式: C16H17ClNO5P
分子量: 369.74
纯度: >98%
溶解度: Soluble in DMSO
储存: Store at -20°C
库存: 现货

Background

Description: IC50 Value: N/A SDZ 220-581 ((S)-alpha-amino 2'chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid) is a potent, competitive antagonist at the NMDA glutamate receptor subtype. in vitro: Wake-promoting doses of LSN2463359 and LSN2814617 attenuated deficits in performance induced by the competitiveNMDA receptor antagonist SDZ 220,581 in two tests of operant behaviour: the variable interval 30 s task and the DMTP task [1]. in vivo: Administration of SDZ 220-581 or CGS 19755 was associated with a robust reduction in PPI, whereas L-701,324, 4-Cl-KYN or MLA failed to alter PPI [2]. With the most active agent, SDZ 220-581, full protection against maximal electroshock seizures (MES) was obtained at oral doses of 10 mg/kg in rats and in mice. The compound had a fast onset (< or = 1 hr) and a long duration (> or = 24 hr) of action [3]. Rats were pretreated with clozapine (0 or 5.0 mg/kg) or haloperidol (0 or 0.1 mg/kg), together with SDZ 220-581 (0 or 2.5 mg/kg), and tested. SDZ 220-581 and SDZ EAB-515 decreased PPI without affecting startle magnitude [4]. Clinical trial: N/A